These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25933139)

  • 1. First Week HCV RNA Level Under the Pegylated Interferon and Ribavirin Treatment Predicts Sustained Virological Response.
    Bayram M; Koksal AR; Alkim H; Boga S; Ergun M; Ozdogan O; Altinkaya E; Alkim C
    Am J Ther; 2016; 23(6):e1612-e1618. PubMed ID: 25933139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
    Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
    J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C; Schwendy S; Möller B; Dikopoulos N; Buggisch P; Encke J; Teuber G; Goeser T; Thimme R; Klinker H; Boecher WO; Schulte-Frohlinde E; Prinzing R; Herrmann E; Zeuzem S; Berg T
    Gastroenterology; 2011 Nov; 141(5):1656-64. PubMed ID: 21784046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    BMC Infect Dis; 2012 Nov; 12():324. PubMed ID: 23181537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Marcellin P; Reau N; Ferenci P; Hadziyannis S; Messinger D; Tatsch F; Jensen D
    J Hepatol; 2012 Jun; 56(6):1276-82. PubMed ID: 22314423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
    Kim CH; Park BD; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS; Lee JI
    Korean J Hepatol; 2009 Mar; 15(1):70-9. PubMed ID: 19346787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin.
    Martinot-Peignoux M; Maylin S; Moucari R; Ripault MP; Boyer N; Cardoso AC; Giuily N; Castelnau C; Pouteau M; Stern C; Aupérin A; Bedossa P; Asselah T; Marcellin P
    Antivir Ther; 2009; 14(4):501-11. PubMed ID: 19578235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Kanda T; Imazeki F; Yonemitsu Y; Mikami S; Takada N; Nishino T; Takashi M; Tsubota A; Kato K; Sugiura N; Tawada A; Wu S; Tanaka T; Nakamoto S; Mikata R; Tada M; Chiba T; Kurihara T; Arai M; Fujiwara K; Kanai F; Yokosuka O
    J Viral Hepat; 2011 Jul; 18(7):e292-7. PubMed ID: 21129130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.